ClinicalTrials.gg
RecruitingNCT06125054Co-BoostUpdated Dec 20, 2024

Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction

A Phase 2 interventional study of Ketamine and Placebo in Cocaine Use Disorder and Cocaine Dependence, sponsored by Dr. med. Marcus Herdener. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Dr. med. Marcus Herdener · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training in individuals with cocaine use disorder. The main questions the investigators aim to answer are:

  • Can the investigators observe a positive, significant effect on percentage of cocaine use days of both interventions combined as well as stand alone interventions?
  • Is there a significant transfer effect of the neurofeedback training?
  • Is there a significant, ketamine-dependent change in glutamate levels in the nucleus accumbens?

Participants will be given ketamine and a realtime fMRI neurofeedback training. Both interventions are placebo-controlled. The investigators will compare the four intervention groups to investigate the effects of the stand-alone effects of the intervention and the combination of it.

Read the detailed description

Cocaine is the most frequently used stimulant worldwide, and its consumption rate in Europe indicates a continuing upward trend. Cocaine use is associated with great harms for affected individuals, their families, and the society. Unfortunately, until today no pharmacotherapy has been approved for the treatment of cocaine use disorder (CUD) due to lack of efficacy of tested compounds.

The investigators therefore propose, to use latest advancements in proton magnetic resonance spectroscopy (1H-MRS) and real time functional magnetic resonance imaging neurofeedback training (rt-fMRI NFT) to develop a neurobiologically informed experimental approach for an individualized and integrated pharmaco-psychotherapy that has the potential to open new avenues for the treatment of CUD, and in addition, to be transferable to other neuropsychiatric conditions.

To improve the efficacy of psychotherapeutic interventions in individuals with CUD, the investigators recently developed an rt-fMRI NFT paradigm based on reward imagery to specifically modify maladaptive reward sensitivity by self-regulating the brain's reward circuits.

Furthermore, using a 1H-MRS technique, the investigators recently demonstrated that a disturbed glutamate homeostasis in the nucleus accumbens (NAcc), an important hub in the brain's reward system, characterizes cue-induced craving in CUD. This indicates that urgently needed novel pharmacotherapies for addiction treatment should target the glutamatergic system.

Thus, to restore the glutamate homeostasis and to boost learning effect of the reward imagery training, the investigators propose to combine reward imagery rt- fMRI NFT with the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, which has direct effects both on glutamatergic signaling and neuroplasticity and has shown therapeutic potential to reduce cocaine craving and cocaine us.

The investigators anticipate a) restoration of the glutamate homeostasis in the NAcc b) changes in maladaptive reward sensitivity resulting from rt-fMRI NFT and c) synergistic effects of the pharmacological and the psychotherapeutic effect due to the ketamine-induced neuroplasticity that might open a window of opportunity for imagery-based learning. The investigators hypothesize that these neurobiological adaptions induced by the described interventions underlie their therapeutic effects on cocaine craving and use.

The effects of ketamine and reward imagery rt-fMRI NFT in individuals with CUD will be tested in a randomized, placebo-controlled, double blind, parallel group study.

02

Conditions studied

  • Cocaine Use Disorder
  • Cocaine Dependence

Keywords

  • Cocaine
  • Cocaine Use
  • Ketamine
  • Reward Sensitivity
  • Glutamate
  • Placebo-controlled
  • Therapeutic effects
  • Mechanistic effects
  • Neurofeedback Training
  • realtime fMRI
03

In context

Cocaine-Related Disorders

416 studies on the registry are indexed under Cocaine-Related Disorders; 12 are open to participants now.

This study's planned enrollment of 120 is above the median of 60 across 313 interventional studies indexed under Cocaine-Related Disorders.

Browse Cocaine-Related Disorders studies →

Lead sponsor

Dr. med. Marcus Herdener is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • as documented by signature
  • Male and female cocaine users 18 to 55 years of age
  • diagnostic and statisical manual (DSM)-5 diagnosis of CUD
  • Willingness to comply with the study protocol as explained by investigator
  • Normal level of language comprehension (German or Swiss-German)

Exclusion criteria

Exclusion Criteria:

  • Current or lifetime psychotic disorders
  • History of severe substance-induced psychosis
  • Current or lifetime bipolar I or II disorders
  • Current suicidality
  • Previous suicide attempts during the last 2 years
  • Current severe alcohol use disorder
  • Current severe cannabis use disorder
  • Current moderate or severe stimulant use disorder (other than cocaine)
  • Current moderate or severe benzodiazepine use disorder
  • Current opioid use disorder
  • First-degree relatives with psychotic disorders
  • Beck Depression Inventory Score greater than 25
  • Unmedicated or unstable hypertension
  • Severe illness (e. g. myocardial ischemia or arrythmias, severe pulmonary secretions, glaucoma, congestive heart failure or angina, significant renal or hepatic impairment)
  • Acute infection (e. g. pulmonary or upper respiratory tract infection)
  • Insufficient treated or uncorrected hyperthyroidism
  • Severe central nervous system related traumas or disorders (e. g. stroke, cerebral trauma with loss of consciousness over more than 24h, epilepsy)
  • Increased intracranial pressure
  • Medication directly affecting glutamate signaling (e. g. anticonvulsant medication)
  • Any unstable psychoactive medication (no changes in compounds within last 4 weeks before start of study)
  • Pregnancy or lactation
  • Women of with no use of medically accepted (e. g.

condoms, contraceptive diaphragm, birth control pill, hormone injection, intrauterine device)

  • >35
  • Allergy, , or other adverse reaction to previous use of ketamine
  • Contradictions to magnetic resonance imaging
  • Concurrent participation in other clinical study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    rt-fMRI NFT / Placebo

    Participants get real time neurofeedback based on an experimental regions' activity and receive a 0.9% saline solution (i.v.) over 40 minutes.

    Drug: Placebo · Behavioral: real-time fMRI neurofeedback training

  • Experimental
    rt-fMRI NFT / Ketamine

    Participants get real time neurofeedback based on an experimental regions' activity and receive 0.71mg ketamine (i.v.) per kilogram bodyweight.

    Drug: Ketamine · Behavioral: real-time fMRI neurofeedback training

  • Placebo comparator
    sham NFT / Placebo

    Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive a 0.9% saline solution (i.v.) over 40 minutes.

    Drug: Placebo · Behavioral: sham real-time fMRI neurofeedback training

  • Experimental
    sham NFT / Ketamine

    Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.71mg ketamine (i.v.) per kilogram bodyweight.

    Drug: Ketamine · Behavioral: sham real-time fMRI neurofeedback training

Interventions

  • single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)

  • DrugPlacebo

    single dose of placebo (0.9% saline solution i.v. over 40 minutes)

    Also known as: 0.9% saline solution

  • Behavioralreal-time fMRI neurofeedback training

    Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated three times.

  • Behavioralsham real-time fMRI neurofeedback training

    Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated three times.

06

What researchers measure

Primary outcomes

  1. Decrease in proportion of cocaine use days

    Between-group comparison of proportion of cocaine use days measured with Time-Line Follow-Back questionnaire for cocaine use on follow-up visit (t3).

    Time frame: Between 5 and 7 weeks after baseline (the first intervention visit)

  2. Changes in fMRI signal of neurofeedback training

    Signal changes assessed with fMRI between the non-neurofeedback run 1 on Interention Visit I (t1) and run 3 on Intervention Visit II (t2).

    Time frame: Between 1 and 2 weeks after baseline (the first neurofeedback training)

  3. Changes in accumbal glutamate levels

    Baseline and acute accumbal glutamate levels assessed with 1H-MRS on Intervention Visit I (t1).

    Time frame: Before and during infusion (same day)

Secondary outcomes

  1. Changes in urine cocaine and cocaine metabolites

    Changes in cocaine and cocaine metabolites via urine analysis as objectified measure of cocaine use.

    Time frame: Baseline (screening visit) up to 19 weeks later (Follow-up Visit)

  2. Cocaine craving

    Changes in cocaine craving score assessed by the Obsessive Compulsive Cocaine Use Scale, ranging from 0 to 56, where higher scores indicate more problematic behavior and thoughts.

    Time frame: From baseline (screening visit) until 38 weeks later (Follow-up Survey)

  3. Severity of cocaine use disorder

    Changes in severity of cocaine use disorder assessed by the Obsessive Compulsive Cocaine Use Scale, ranging from 0 to 56, where higher scores indicate more problematic behavior and thoughts.

    Time frame: From baseline (screening visit) until 38 weeks later (Follow-up Survey)

  4. Current motivation to change cocaine use behaviour

    Changes in current motivation to change cocaine use behaviour assessed by an visual analogue scale ranging from 0 to 30 where higher scores indicate a higher motivation to change.

    Time frame: From baseline (screening visit) until 38 weeks later (Follow-up Survey)

  5. Hedonic capacity

    Changes in hedonic capacity measured by the Trait Hedonic Capacity Scale, ranging from 16 to 80, where a higher score indicates a higher hedonic capacity.

    Time frame: From baseline (screening visit) until 38 weeks later (Follow-up Survey)

  6. Experience of pleasure across different domains

    Changes in the experience of pleasure across different domains assessed by the Domains of Pleasure Scale, ranging from 0 to 210 where a higher score indicates a higher experience of pleasure.

    Time frame: From baseline (screening visit) until 38 weeks later (Follow-up Survey)

  7. Emotion regulation skills

    Changes in emotion regulation skills measured with the Negative Mood Regulation expectancies Scale, ranging from 30 to 150 where higher scores indicate higher emotion regulation skills.

    Time frame: Baseline (screening visit) and up to 19 weeks later (Follow-up Visit)

  8. Depressive symptoms

    Changes in depressive symptoms measured with the Beck Depression Inventory. The scale ranges from 0 to 63 where higher scores indicate more severe depressive symptoms.

    Time frame: Baseline (screening visit), up to 14 weeks later (Intervention Visit II), and up to 19 weeks later (Follow-up Visit)

  9. Perceived stress

    Changes in perceived stress assessed with a subscale of the Stress \& Coping Inventory, ranging from 21 to 147 where higher scores indicate higher perceived stress.

    Time frame: Baseline (screening visit), up to 19 weeks later (Follow-up Visit), and up to 38 weeks later (Follow-up Survey)

  10. Self-esteem

    Changes in self-esteem assessed with the Rosenberg Self-esteem Scale, ranging from 0 to 30 where higher scores indicate a higher self-esteem.

    Time frame: Baseline (screening visit), up to 14 weeks later (Intervention Visit II), up to 19 weeks later (Follow-up Visit), and up to 38 weeks later (Follow-up Survey)

  11. Self-efficacy, optimism, and pessimism

    Changes in Self-efficacy, optimism, and pessimism assessed with the Questionnaire for Self-efficacy, Optimism, and Pessimism (KSWOP-9), ranging from 9 to 36 where higher scores indicate higher self-efficacy, optimism, and pessimism, respectively.

    Time frame: Baseline (screening visit), up to 14 weeks later (Intervention Visit II), up to 19 weeks later (Follow-up Visit), and up to 38 weeks later (Follow-up Survey)

  12. Subjective effects of ketamine infusion

    Assess the acute subjective effects of the infusion with the Five-Dimension Altered State of Consciousness Questionnaire (5D-ASC), where the global score and each of the 11 subscales range from 0 to 100 and higher scores indicate the occurence of altered states of consciousness.

    Time frame: 2 hours post infusion

  13. Effects of ketamine infusion on mystic experiences

    Assess the acute subjective effects of the infusion with the Hood's Mysticism Scale, ranging from 20 to 100 where higher scores indicate the occurence of mystic experiences.

    Time frame: 2 hours post infusion

  14. Sustained changes in accumbal glutamate levels

    Assess sustained effects of the infusion and the neurofeedback training on baseline accumbal glutamate levels with 1H-MRS.

    Time frame: Baseline (pre infusion, Intervention Visit I) and up to 2 weeks after infusion and neurofeedback training (Intervention Visit II)

  15. Glutamate levels during craving paradigm

    Assess the effects of the infusion and the neurofeedback training on glutamate levels measured by 1H-MRS during a craving paradigm.

    Time frame: Up to 2 weeks post infusion and neurofeedback training

  16. Changes in Brain Derived Neurotrophic Factor

    Assess changes in Brain Derived Neurotrophic Factor (BDNF) through blood analysis before and after the infusion.

    Time frame: 0.5 hours pre infusion and 2 hours post infusion

07

Study locations

1 of 1 sites recruiting
  • Psychiatric University Hospital Zurich, University of Zurich
    Zürich, 8032, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Our data will be published on the website of Open Science Framework.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After the publication of our data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2025, 22 months after the start.

Of 22 phase 2 interventional studies under Cocaine-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Nov 9, 2023
StartActual
Feb 5, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Mar 2026
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06125054
Lead sponsor
Dr. med. Marcus Herdener
Responsible party
Dr. med. Marcus Herdener (Dr. med., Psychiatric University Hospital, Zurich) — Sponsor-investigator
First posted
Nov 9, 2023
Start date
Feb 5, 2024
Primary completion
Dec 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Dec 20, 2024

Study contacts

Marcus Herdener, PD Dr. med.
Contact
marcus.herdener@bli.uzh.ch
+41583845810
Etna Engeli, Dr.
Contact
etna.engeli@bli.uzh.ch
+41583842771

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion